I agree that this site is using cookies. You can find further informations here.
X
Schellekens, Huub
180  results:
Search for persons X
?
1

Nature of the Interaction of Alpha-D-Mannose and Escherichi..:

Scaglione, Francesco ; Minghetti, Paola ; Ambrosio, Francesco...
Therapeutic Innovation & Regulatory Science.  57 (2023)  6 - p. 1153-1166 , 2023
Link: https://doi.org/10.1007/..
 
?
2

Translatability of preclinical to early clinical tolerable ..:

Ferreira, Guilherme S. ; Dijkstra, Francis M. ; Veening-Griffioen, Désirée H....
Translational Psychiatry.  13 (2023)  1 - p. , 2023
Link: https://doi.org/10.1038/..
 
?
3

Comparison of drug efficacy in two animal models of type 2 ..:

Ferreira, Guilherme S. ; Veening-Griffioen, Désirée H. ; Boon, Wouter P.C....
European Journal of Pharmacology.  879 (2020)  - p. 173153 , 2020
Link: https://doi.org/10.1016/..
 
?
4

Protein Quality Testing in the Era of Personalized Medicine:

Doevendans, Erik ; Schellekens, Huub
Journal of Pharmaceutical Sciences.  109 (2020)  10 - p. 2962-2968 , 2020
Link: https://doi.org/10.1016/..
 
?
5

Liposome-targeted recombinant human acid sphingomyelinase: ..:

Aldosari, Mohammed H. ; de Vries, Robert P. ; Rodriguez, Lucia R....
European Journal of Pharmaceutics and Biopharmaceutics.  137 (2019)  - p. 185-195 , 2019
Link: https://doi.org/10.1016/..
 
?
6

A standardised framework to identify optimal animal models ..:

S. Ferreira, Guilherme ; Veening-Griffioen, Désirée H. ; Boon, Wouter P. C....
PLOS ONE.  14 (2019)  6 - p. e0218014 , 2019
Link: https://doi.org/10.1371/..
 
?
7

Are we ready to close the discussion on the interchangeabil..:

Ebbers, Hans C. ; Schellekens, Huub
Drug Discovery Today.  24 (2019)  10 - p. 1963-1967 , 2019
Link: https://doi.org/10.1016/..
 
?
8

Correction: A standardised framework to identify optimal an..:

Ferreira, Guilherme S. ; Veening-Griffioen, Désirée H. ; Boon, Wouter P. C....
PLOS ONE.  14 (2019)  7 - p. e0220325 , 2019
Link: https://doi.org/10.1371/..
 
?
9

Are some animal models more equal than others? A case study..:

Veening-Griffioen, Désirée H. ; Ferreira, Guilherme S. ; van Meer, Peter J.K....
European Journal of Pharmacology.  859 (2019)  - p. 172524 , 2019
Link: https://doi.org/10.1016/..
 
?
10

Immunogenicity of Innovative and Biosimilar Monoclonal Anti..:

Doevendans, Erik ; Schellekens, Huub
Antibodies.  8 (2019)  1 - p. 21 , 2019
Link: https://doi.org/10.3390/..
 
?
11

Quality Comparison of Biosimilar and Copy Filgrastim Produc..:

Halim, Liem Andhyk ; Márquez, Maripaz ; Maas-Bakker, Roel F....
Pharmaceutical Research.  35 (2018)  11 - p. , 2018
Link: https://doi.org/10.1007/..
 
?
12

Evaluation of the suitability of a Sprague Dawley rat model..:

Span, Kimberley ; Pieters, Ebel H.E. ; Brinks, Vera..
Journal of Pharmacological and Toxicological Methods.  91 (2018)  - p. 7-17 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Making individualized drugs a reality:

Schellekens, Huub ; Aldosari, Mohammed ; Talsma, Herre.
Nature Biotechnology.  35 (2017)  6 - p. 507-513 , 2017
Link: https://doi.org/10.1038/..
 
?
14

Iron nanomedicines induce Toll-like receptor activation, cy..:

Verhoef, Johan J.F. ; de Groot, A. Marit ; van Moorsel, Marc...
Biomaterials.  119 (2017)  - p. 68-77 , 2017
Link: https://doi.org/10.1016/..
 
?
15

How institutional logics hamper innovation: The case of ani..:

Kooijman, Marlous ; Hekkert, Marko P. ; van Meer, Peter J.K...
Technological Forecasting and Social Change.  118 (2017)  - p. 70-79 , 2017
Link: https://doi.org/10.1016/..
 
1-15